Cobimetinib, another MEK inhibitor developed by Exelixis and Genentech (Roche), had an encouraging performance in unresectable and metastatic BRAFV600E-mutant melanoma when applied in combination with vemurafenib. Here, MAP2K7 is linked to melanoma.